PMU26 COST-UTILITY ANALYSIS OF CANCER AND NON-CANCER CONDITIONS: A SYSTEMATIC REVIEW OF DIFFERENT LEVELS OF DISEASE PREVENTION AND CONTROL, 1990 TO 2016 von Ekwueme, D., Khushalani, J.S., Chambers, J., D'Cruz, B., Neumann, P.J.

Volltext

PMU16 THE ESTIMATED ECONOMIC BURDEN OF CANCERS ATTRIBUTABLE TO SUBOPTIMAL DIET IN THE UNITED STATES von Khushalani, J.S., Cudhea, F., Ekwueme, D.U., Harris, D., Mozaffarian, D., Zhang, F.F.

Volltext

PCN383 - ESTIMATING THE HEALTH IMPACT OF INCREASING BREAST AND CERVICAL CANCER SCREENING IN THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM AMONG LOW-INCOME WOMEN I... von Ekwueme, D.U., Pollack, L.M., Hung, M., Khushalani, J.S., Miller, J.W., Chang, S.

Volltext

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint... von Chesney, Jason, Lewis, Karl D, Kluger, Harriet, Hamid, Omid, Whitman, Eric, Thomas, Sajeve, Wermke, Martin, Cusnir, Mike, Domingo-Musibay, Evidio, Phan, Giao Q, Kirkwood, John M, Hassel, Jessica C, Orloff, Marlana, Larkin, James, Weber, Jeffrey, Furness, Andrew J S, Khushalani, Nikhil I, Medina, Theresa, Egger, Michael E, Graf Finckenstein, Friedrich, Jagasia, Madan, Hari, Parameswaran, Sulur, Giri, Shi, Wen, Wu, Xiao, Sarnaik, Amod

Volltext

1103P Real-world efficacy of relatlimab and nivolumab in advanced or resectable melanoma von Karapetyan, L., Aflatooni, S., Ward, K., Withycombe, B., Kalos, D., Mo, Q., Eroglu, Z., Brohl, A.S., Markowitz, J., Tarhini, A., Messina, J., Tsai, K.Y., Perez, M., Zager, J.S., Sarnaik, A., Neves, R.I., Sondak, V., Khushalani, N.I.

Volltext

LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTE... von Weber, J.S., Minor, D.R., D'Angelo, S.P., Hodi, F.S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N.I., Miller, W.H., Grob, J-J., Lao, C., Linette, G., Grossmann, K., Hassel, J.C., Lorigan, P., Maio, M., Sznol, M., Lambert, A., Yang, A., Larkin, J.

Volltext

A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus Investigator'S Choice Chemotherapy (Icc) in Patients with Advanced Melanoma After Prior... von Weber, J.S., Minor, D.R., D'Angelo, S.P., Hodi, F.S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N.I., Miller, W.H., Grob, J-J., Lao, C., Linette, G., Grossmann, K., Hassel, J.C., Lorigan, P., Maio, M., Sznol, M., Lambert, A., Yang, A., Larkin, J.

Volltext